

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on December 1, 2006.

TOWNSEND and TOWNSEND and CREW LLP

By:

Anne C. Kundel

PATENT
Attorney Docket No.: 021044-005820US
Client Reference No.: P.0128.02.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LORENS et al.

Application No.: 10/696,909

Filed: October 29, 2003

For: MODULATORS OF
ANGIOGENESIS AND
TUMORIGENESIS

Confirmation No.: 9257

Examiner: Peter J. Redding

Art Unit: 1642

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

Also enclosed is a copy of the supplementary partial European Search report corresponding to the European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

CERTIFICATION

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
BLK:ack

| | | | | | |
|-------------------------------|---|----|---|------------------------|------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/686,909 |
| | | | | Filing Date | October 29, 2003 |
| | | | | First Named Inventor | Lorens, James B. |
| | | | | Art Unit | 1642 |
| | | | | Examiner Name | Peter J. Redding |
| Sheet | 1 | of | 1 | Attorney Docket Number | 021044-005820US |

| | | | | | |
|------------------------------|-----------------------|---|--------------------------------|--|---|
| U.S. PATENT DOCUMENTS | | | | | |
| Examiner Initials* | Cite No. ¹ | Document Number Number/Kind Code ² (where applicable) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|---------------------------------|-----------------------|---------------------------|---------------------|--------------------------------|---|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Country Code ⁴ | Number ⁴ | | | | |
| B1 | WO | 2003/76309 | A2 | 12-21-2003 | Vrije Universiteit Instituut Voor Biotechnologie VZW | | <input type="checkbox"/> |
| B2 | WO | 2001/32926 | A2 | 05-10-2001 | Curagen Corporation et al. | | <input type="checkbox"/> |
| B3 | WO | 2001/63261 | A1 | 08-30-2001 | MUSC Foundation for Research Development | | <input type="checkbox"/> |
| B4 | WO | 2002/081627 | A2 | 10-17-2002 | Allergan, Inc. | | <input type="checkbox"/> |
| B5 | WO | 2004/058147 | A2 | 01-22-2004 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | | <input type="checkbox"/> |

| | | | | | | | |
|--|-----------------------|---|--|--|--|--|--------------------------|
| NON PATENT LITERATURE DOCUMENTS | | | | | | | |
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | | T ² |
| | B6 | O'DONNELL, K., et al., "Expression of Receptor Tyrosine Kinase Axl and Its Ligand Gas6 in Rheumatoid Arthritis: Evidence for a Novel Endothelial Cell Survival Pathway," <i>American Journal of Pathology</i> , April 1999, Vol. 154, No. 4, pp. 1171-1180. | | | | | <input type="checkbox"/> |
| | B7 | ZANTEK, N., et al., "MCF-10A-NeoST: A New Cell System for Studying Cell-ECM and Cell-Cell Interactions In Breast Cancer," <i>Clinical Cancer Research</i> , November 2001, Vol. 7, pp. 3640-3648. | | | | | <input type="checkbox"/> |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.